ClinicalTrials.gg
Not yet recruitingNCT07835295REMI-MEPUpdated Sep 22, 2026

REMIfentanil (2 vs. 4 mcg/kg) Facilitated Intubation Without Neuromuscular Blockade Versus Succinylcholine and Rocuronium With Sugammadex for Endotracheal Intubation in Spine Surgery Requiring Motor Evoked Potential Monitoring

A Phase 4 interventional study of Low-Dose Remifentanil and High-Dose Remifentanil in Airway Management and Endotracheal Intubation, sponsored by Mayo Clinic. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-22.

Sponsored by Mayo Clinic · Phase 4, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
316
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The purpose of this research is to compare four commonly used anesthesia medication strategies for placing a breathing tube in patients undergoing spine surgery that requires motor evoked potential (MEP) monitoring.

Read the detailed description

Specifically, the study will compare two different doses of remifentanil, succinylcholine, and rocuronium followed by sugammadex to determine which approach provides the best conditions for endotracheal intubation while minimizing interference with nerve monitoring. Researchers will also evaluate how these approaches affect blood pressure and heart rate during anesthesia induction, the quality of motor evoked potential monitoring, the need for additional airway interventions or rescue medications, and the occurrence of side effects such as muscle soreness after surgery.

02

Conditions studied

  • Airway Management
  • Endotracheal Intubation
03

In context

Lead sponsor

Mayo Clinic is the lead sponsor of 3,271 studies on the registry; 671 are open to participants now.

Of its 452 completed or terminated interventional studies of FDA-regulated products, 322 (71%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (ASA) physical status I-III
  • Scheduled for elective spine surgery (cervical, thoracic, or lumbar) requiring intraoperative MEP monitoring
  • Able to provide written

Exclusion criteria

Exclusion Criteria:

  • Known or suspected difficult airway (Mallampati class IV, history of difficult intubation, limited mouth opening \< 3 cm, limited neck extension)
  • (BMI) > 40 kg/m2
  • Known allergy or to remifentanil, succinylcholine, rocuronium, sugammadex, or propofol
  • Personal or family history of malignant hyperthermia
  • Known or suspected pseudocholinesterase deficiency
  • Conditions predisposing to succinylcholine-induced hyperkalemia (e.g., major burns within the last year, denervation injuries or upper motor neuron lesions within 6 months, severe crush injuries, prolonged immobilization > 72 hours, known hyperkalemia > 5.5 mEq/L)
  • Severe preoperative motor deficit (manual muscle testing ≤ 2/5 in monitored extremities)
  • Neuromuscular disorders (e.g., myasthenia gravis, muscular dystrophy, Guillain-Barre syndrome, prior stroke with residual motor deficits)
  • Severe cardiovascular disease (e.g., \< 30%, unstable angina, myocardial infarction within 3 months)
  • Severe bradycardia (heart rate \< 50 bpm) or high-grade atrioventricular block without a pacemaker
  • Current use of medications affecting neuromuscular function (aminoglycosides, magnesium infusion, certain antiepileptic meds, etc.)
  • Emergency surgery
  • High aspiration risk (e.g., uncontrolled gastroesophageal reflux disease)
  • Pregnancy or breastfeeding
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 4
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
316 participants (estimated)

Study arms

  • Experimental
    Low-Dose Remifentanil

    Participants receive remifentanil 2 mcg/kg intravenous bolus after standardized propofol induction.

    Drug: Low-Dose Remifentanil

  • Experimental
    High-Dose Remifentanil

    Participants receive remifentanil 4 mcg/kg intravenous bolus after standardized propofol induction.

    Drug: High-Dose Remifentanil

  • Active comparator
    Succinylcholine Control

    Participants receive succinylcholine 1 mg/kg intravenous bolus after standardized propofol induction.

    Drug: Succinylcholine

  • Active comparator
    Rocuronium With Sugammadex

    Participants receive rocuronium 0.6 mg/kg intravenous bolus after standardized propofol induction, followed by sugammadex reversal after intubation according to protocol.

    Drug: Rocuronium · Drug: Sugammadex

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Clinically Acceptable Intubating Conditions

    Clinically acceptable intubating conditions are defined as intubating conditions rated as excellent or good using a standardized intubating conditions assessment. The assessment includes ease of laryngoscopy, vocal cord position and movement, and participant reaction to intubation. Overall intubating conditions are categorized as excellent, good, or poor. Excellent and good conditions will be counted as clinically acceptable, and poor conditions will be counted as not clinically acceptable. The outcome will be reported as the percentage of participants in each arm with clinically acceptable intubating conditions.

    Time frame: During the first endotracheal intubation attempt after study drug administration, assessed within approximately 10 minutes after induction of anesthesia

Secondary outcomes

  1. Percentage of Participants With Excellent Intubating Conditions

    Excellent intubating conditions are defined as all assessed intubating condition domains rated as excellent. Domains include ease of laryngoscopy, vocal cord position and movement, and participant reaction to intubation. The outcome will be reported as the percentage of participants in each arm with excellent intubating conditions.

    Time frame: During the first endotracheal intubation attempt after study drug administration, assessed within approximately 10 minutes after induction of anesthesia

  2. Percentage of Participants With Successful First-Attempt Endotracheal Intubation

    Successful first-attempt endotracheal intubation is defined as successful placement of the endotracheal tube on the first laryngoscopy attempt, confirmed by capnography over four respiratory cycles. The outcome will be reported as the percentage of participants in each arm with successful first-attempt intubation.

    Time frame: Within 5 minutes after the study drug administration.

  3. Cormack-Lehane Grade of Glottic Visualization grade

    Glottic visualization will be assessed using the Cormack-Lehane grading system. Grades range from 1 to 4, with lower grades indicating better visualization of the glottis and higher grades indicating poorer visualization. The outcome will be reported by grade for each arm.

    Time frame: During the first laryngoscopy attempt after study drug administration.

  4. Intubation Difficulty Scale Score

    Intubation difficulty will be assessed using the Intubation Difficulty Scale. Scores range from 0 to infinity, with 0 indicating an easy intubation and scores greater than 5 indicating difficult intubation. The outcome will be reported as the Intubation Difficulty Scale score for each arm.

    Time frame: During endotracheal intubation after study drug administration, assessed within approximately 10 minutes after induction of anesthesia

  5. Number of Laryngoscopy Attempts

    The number of laryngoscopy attempts required to achieve successful endotracheal intubation will be recorded. The outcome will be reported as the number of attempts for each arm.

    Time frame: During endotracheal intubation after study drug administration, assessed within approximately 10 minutes after induction of anesthesia

  6. Time From Study Drug Administration to Successful Endotracheal Intubation

    Time to successful endotracheal intubation is defined as the elapsed time, in seconds, from administration of the assigned study drug to successful endotracheal tube placement confirmed by capnography. The outcome will be reported in seconds for each arm.

    Time frame: From study drug administration until successful endotracheal intubation, assessed within approximately 10 minutes after induction of anesthesia

  7. Percentage of Participants Requiring Rescue Neuromuscular Blockade

    Rescue neuromuscular blockade is defined as administration of succinylcholine in participants assigned to a remifentanil arm because of poor intubating conditions or unsuccessful intubation after two attempts. The outcome will be reported as the percentage of participants in the remifentanil arms who required rescue neuromuscular blockade.

    Time frame: During attempted endotracheal intubation after study drug administration, assessed within approximately 10 minutes after induction of anesthesia

  8. Percentage of Participants Requiring an Alternative Intubation Technique

    Alternative intubation technique is defined as use of an additional airway technique or device, such as a bougie or different laryngoscope blade, to facilitate endotracheal intubation. The outcome will be reported as the percentage of participants in each arm requiring an alternative intubation technique.

    Time frame: During attempted endotracheal intubation after study drug administration, assessed within approximately 10 minutes after induction of anesthesia

  9. Percentage of Participants With Movement During Intubation

    Participant movement during intubation will be assessed by the blinded observer and recorded as present or absent. Movement may include diaphragmatic movement, coughing, bucking, or other clinically observable movement during intubation. The outcome will be reported as the percentage of participants in each arm with movement during intubation.

    Time frame: Within 5 minutes after the study drug administration

  10. Percentage of Participants Requiring Adjunct Medication to Facilitate Induction or Intubation

    Adjunct medication is defined as any additional medication administered to facilitate induction or intubation beyond the assigned study drug and standardized induction regimen. Examples may include midazolam, fentanyl, or lidocaine. The outcome will be reported as the percentage of participants in each arm requiring adjunct medication.

    Time frame: From induction of anesthesia through successful endotracheal intubation, assessed within approximately 10 minutes after induction of anesthesia

  11. Change in Mean Arterial Pressure

    Mean arterial pressure will be measured using standard intraoperative monitoring. Change from baseline will be calculated as the post-induction or intubation value minus the baseline value recorded before induction of anesthesia. The outcome will be reported for each arm.

    Time frame: From baseline before induction of anesthesia through successful endotracheal intubation, assessed within approximately 10 minutes after induction of anesthesia

  12. Change in Heart Rate

    Heart rate will be measured using standard intraoperative monitoring. Change from baseline will be calculated as the post-induction or intubation value minus the baseline value recorded before induction of anesthesia. The outcome will be reported for each arm.

    Time frame: From baseline before induction of anesthesia through successful endotracheal intubation, assessed within approximately 10 minutes after induction of anesthesia

  13. Percentage of Participants With Hypotension, Bradycardia, or Oxygen Desaturation During Induction and Intubation

    Hypotension, bradycardia, and oxygen desaturation occurring during induction and intubation will be recorded according to protocol-defined safety monitoring procedures. The outcome will be reported as the percentage of participants in each arm with one or more of these events.

    Time frame: From induction of anesthesia through successful endotracheal intubation, assessed within approximately 10 minutes after induction of anesthesia

  14. Percentage of Participants With Intubation-Related Complications

    Intubation-related complications include dental trauma, aspiration, airway trauma, or other clinically documented complications related to endotracheal intubation. The outcome will be reported as the percentage of participants in each arm with at least one intubation-related complication.

    Time frame: During endotracheal intubation after study drug administration, assessed within approximately 10 minutes after induction of anesthesia

  15. Time From Successful Endotracheal Intubation to Acquisition of Baseline Motor Evoked Potentials

    Time to baseline motor evoked potential acquisition is defined as the elapsed time, in minutes, from successful endotracheal intubation to acquisition of baseline motor evoked potential signals according to institutional neuromonitoring procedures. The outcome will be reported in minutes for each arm.

    Time frame: From successful endotracheal intubation until acquisition of baseline motor evoked potentials before patient positioning

  16. Motor Evoked Potential Signal Quality

    Motor evoked potential signal quality will be assessed using neuromonitoring documentation, including signal amplitude and successful detection of baseline signals. The outcome will be reported for each arm using the protocol-specified signal quality variables.

    Time frame: At baseline neuromonitoring assessment after successful endotracheal intubation and before patient positioning

  17. Percentage of Participants With Postoperative Myalgia at 24 Hours

    Postoperative myalgia is defined as participant-reported muscle pain after surgery, assessed at approximately 24 hours postoperatively. The outcome will be reported as the percentage of participants in each arm with postoperative myalgia at 24 hours.

    Time frame: 24 hours after surgery

  18. Percentage of Participants With Postoperative Myalgia at 48 Hours

    Postoperative myalgia is defined as participant-reported muscle pain after surgery, assessed at approximately 48 hours postoperatively. The outcome will be reported as the percentage of participants in each arm with postoperative myalgia at 48 hours.

    Time frame: 48 hours after surgery

  19. Postoperative Opioid Consumption

    Postoperative opioid consumption will be obtained from the medical record and summarized using the protocol-specified opioid consumption unit or conversion method. The outcome will be reported for each arm over the postoperative assessment period.

    Time frame: From completion of surgery through 48 hours after surgery

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2026; primary completion for Sep 2028, 24 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2026
First posted
Sep 22, 2026
StartEst.
Sep 2026
Primary completionEst.
Sep 2028
CompletionEst.
Jan 2029
Last update
Sep 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07835295
Lead sponsor
Mayo Clinic
Responsible party
Shaun Gruenbaum (Principal Investigator, Mayo Clinic) — Principal investigator
First posted
Sep 22, 2026
Start date
Sep 2026 (estimated)
Primary completion
Sep 2028 (estimated)
Completion
Jan 2029 (estimated)
Last update
Sep 22, 2026

Study contacts

Mariel Anne Reyes
Contact
reyes.mariel@mayo.edu
904-953-4797
Shaun Gruenbaum, MD
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Remifentanil

Start the discussion